Anjarium

[Anjarium @AnjariumBio]

We are thrilled to announce ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology Officer https://t.co/GflxSE9yKI

[Anjarium @AnjariumBio]

Today we report that we have appointed Gaurav Shah as Chairperson and Douglas Fambrough as Non-executive Director https://t.co/jvcPXfwEmb

[startupticker @startuptickerCH]

Schlieren biotech Anjarium unlocks the potential of gene therapy. In addition to top-tier investors supporting the idea, the company has obtained the Innosuisse Certificate, symbolising its readiness for growth. @AnjariumBio @Innosuisse https://t.co/QdxmTl42hh

[Anjarium @AnjariumBio]

We are thrilled to announce that we have raised CHF55.5M ($61M) Series A to develop our next-generation non-viral gene therapies.
The round was co-led by @Abingworthbio and @Gimv, alongside Omega Funds, Pfizer Ventures and Surveyor (a Citadel company)
https://t.co/nYRvrw3VYx

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The first drug candidates harnessing exosomes as drug delivery systems for small molecules, DNA, RNA and other biologics are now entering clinical trials https://t.co/pwmfMWFKjc - find out more about the burgeoning opportunities in the field in this news article by @megan_cully

[Anjarium @AnjariumBio]

Great article about the exciting times in the field! https://t.co/kuUFjf96IV

[Invest Switzerland @investCH]

We are ready for #BIODigital and super excited to present you our top-notch Swiss #biotech startups!

See you in Switzerland - where global pharma meets smart startups

#BIO2020 #SwissTech #SwissInnovation
@HofSwitzerland, @swisstech